RxDoctor Payments Data

Anthony Messina, MD

Cardiovascular Disease · Poughkeepsie, NYNPI 1629253547

Payments from drug & device makers

$9,281in general payments, 2019–2025

Across 82 payments — averaging $113.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$8K
  • Novartis$284
  • Amgen$233
  • Heartflow, Inc.$134
  • AstraZeneca$131
  • Bridgebio Pharma, Inc.$109
  • plus $573 from 13 others

What the payments were for

  • Consulting fees$400%
  • Speaking & faculty fees$6,67072%
  • Travel & lodging$5706%
  • Food & beverage$1,70318%
  • Education$2983%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,281 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$343,590
Medicare patients
1,995
Services billed
5,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban467$591,312
EntrestoSacubitril/Valsartan60$93,505
XareltoRivaroxaban56$70,274
FarxigaDapagliflozin Propanediol15$25,702
Repatha SureclickEvolocumab25$24,808
JardianceEmpagliflozin16$15,219
BrilintaTicagrelor13$15,008
Dofetilide38$14,206
Praluent PenAlirocumab11$13,614
Metoprolol Succinate706$12,685
Rosuvastatin Calcium384$6,992
Atorvastatin Calcium490$5,622
NexlizetBempedoic Acid/Ezetimibe11$4,415
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$3,415
Carvedilol322$3,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$591,312467 claims
NovartisEntresto$284$93,50560 claims
Johnson & JohnsonXarelto$37$70,27456 claims
AstraZenecaFarxiga, Brilinta$131$40,71028 claims
Boehringer IngelheimJardiance$94$15,21916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →